- cafead Oct 07, 2020 at 11:12: AM
via Eli Lilly is hustling to the FDA with its antibody therapy for a speedy emergency use authorization (EUA) as it also reveals new data for a combo therapy.
Lilly said that it has now submitted an initial request for EUA for LY-CoV555 on its own, specifically in higher-risk patients who have been recently diagnosed with mild to moderate COVID-19. It will wait until November to ask for a EUA on the new cocktail therapy.
article source
Lilly said that it has now submitted an initial request for EUA for LY-CoV555 on its own, specifically in higher-risk patients who have been recently diagnosed with mild to moderate COVID-19. It will wait until November to ask for a EUA on the new cocktail therapy.
article source